SCHEMBL6713227

SCHEMBL6713227

O=C(O)Cc1cc[c]cc1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.39
BCAT2 O15382 1/20 0.39
KDM4E B2RXH2 3/20 0.37
CYP1A2 P05177 2/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.35
HSD17B10 Q99714 2/20 0.35
DUSP3 P51452 1/20 0.35
PTPN5 P54829 1/20 0.35
PTPN11 Q06124 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
CXCL8 P10145 3/20 0.34
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALOX15 P16050 1/20 0.33
APEX1 P27695 1/20 0.33
PTGS2 P35354 2/20 0.33
AKR1B10 O60218 1/20 0.33
UGT1A9 O60656 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7771341 0.82 AKR1B1 (0.43) AKR1B1BCAT2KDM4ECYP1A2MAPT
SCHEMBL9580151 0.80 AKR1B1 (0.52) AKR1B1KDM4ECYP1A2MAPTTDP1
SCHEMBL22344551 0.77 AKR1B1 (0.42) AKR1B1TDP1CXCL8PTGS2AKR1B10
SCHEMBL22344518 0.77 AKR1B1 (0.39) AKR1B1BCAT2KDM4ECYP1A2MAPT
SCHEMBL22344588 0.77 CXCL8 (0.41) AKR1B1KDM4ECYP1A2MAPTTDP1
SCHEMBL1441910 0.77 AKR1B1 (0.39) AKR1B1BCAT2KDM4ECYP1A2MAPT
SCHEMBL27810240 0.75 GABRP (0.44) KDM4ECYP1A2MAPTTDP1HSD17B10
SCHEMBL490677 0.74 ALDH1A1 (0.48) KDM4ECYP1A2MAPTTDP1HSD17B10
SCHEMBL11051979 0.74 AKR1B1 (0.41) AKR1B1MAPTTDP1HSD17B10ALOX15
SCHEMBL6762399 0.74 AKR1B1 (0.55) AKR1B1KDM4ECYP1A2MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004065411-A2 PEPTIDES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2004-08-05 WO claimed
US-20040138104-A1 Peptides THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, 2004-07-15 US claimed
WO-2004065411-A2 PEPTIDES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2004-08-05 WO disclosed
US-20040138104-A1 Peptides THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138104-A1 Peptides PTMS, VIP, CPB1 AKR1B1 1526/4885BCAT2 37/4885KDM4E 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.